medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-14-36-41medsovet-1459Research ArticleЗАБОЛЕВАНИЯ ПИЩЕВОДА И ЖЕЛУДКАESOPHAGEAL AND GASTRIC DISEASESНарушения моторики желудочно-кишечного тракта в практике терапевта и некоторые лечебные подходыDisturbances of motility of gastrointestinal tract in practice of therapist and some therapeutic approachesМинушкинО. Н.MinushkinO. N.

д.м.н., профессор

MD, Prof.

МасловскийЛ. В.MaslovskyL. V.

д.м.н.

MD

АникинаН. Ю.AnikinaN. Y.

к.м.н.

PhD in medicine, department of therapy and gastroenterology

Центральная государственная медицинская академия Управления делами Президента Российской Федерации, МоскваРоссияCentral State Medical Academy of President RF Affairs ManagementRussian Federation2016301220160143641Copyright © Минушкин О.Н., Масловский Л.В., Аникина Н.Ю., 20162016Минушкин О.Н., Масловский Л.В., Аникина Н.Ю.Minushkin O.N., Maslovsky L.V., Anikina N.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1459

В настоящее время факт широкой распространенности нарушений моторики верхних отделов желудочно-кишечного тракта (ЖКТ) не вызывает сомнения. Нарушенная моторика может быть ведущим патогенетическим фактором, например при гастроэзофагеальной рефлюксной болезни (ГЭРБ), дуоденостазе, а может сопутствовать другим заболеваниям с различным патогенезом (хронический гастрит, хронический холецистит, дискинезии желчевыводящих путей и др.). Наиболее характерными жалобами при этих состояниях будут изжога, тошнота, рвота, тяжесть после еды, чувство быстрого насыщения, отрыжка. ГЭРБ – заболевание, связанное с нарушением двигательной функции верхних отделов ЖКТ. Распространенность заболевания составляет 40–60% у взрослого населения. 

Currently the fact of the high prevalence rate of disturbance of motility of the upper departments of the gastrointestinal tracts doesn’t cause any doubts. The disturbed motility might be a leading pathogenic factor , for instance, in gastroesophageal reflux disease (GERD), duodenostasis, and might accompany other diseases with various pathogenesis (chronic gastritis, chronic cholecystisis, dyskinesia of bile ducts etc.). The most characteristics complaints at these states will be: heartburn, nausea, vomiting, postprandial heaviness, feeling of early satiety, belching. GERD – a disease related to disturbance of the motor function of GIT upper departments. The prevalence of the disease in adult population ranges from 40 to 60%. 

желудочно-кишечный трактмоторикатерапиядомперидонМотилакgastrointestinal tractmotilitytherapydomperidoneMotilakReferencesReynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am, 1989, 18: 437-57.Reynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am, 1989, 18: 437-57.Abrahamsson H. Gastrointestinal motility disorders in patients with diabetes mellitus. J Intern Med, 1995, 237: 403-9.Abrahamsson H. Gastrointestinal motility disorders in patients with diabetes mellitus. J Intern Med, 1995, 237: 403-9.Malagelada J-R, Azpiroz F, Mearin F. Gastroduodenal motor function in health and disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease: pathophysiology, diagnosis, management. 5th ed. Philadelphia: WB Saunders, 1993: 486-508.Malagelada J-R, Azpiroz F, Mearin F. Gastroduodenal motor function in health and disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease: pathophysiology, diagnosis, management. 5th ed. Philadelphia: WB Saunders, 1993: 486-508.Joseph A Barone. Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist. Ann Pharmacother, 1999, 33: 429-40.Joseph A Barone. Domperidone: A Peripherally Acting Dopamine2-Receptor Antagonist. Ann Pharmacother, 1999, 33: 429-40.Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum, 1993, 36: 696-708.Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum, 1993, 36: 696-708.Broggden R, Carmine A, Heel R et al. Domperidon: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drug, 1988, 1(Jan): 1-34.Broggden R, Carmine A, Heel R et al. Domperidon: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drug, 1988, 1(Jan): 1-34.Johnson AG. Domperidone in the treatment of gastroesophageal reflux disease. In: Scarpignato C, ed. Advances in drug therapy of gastroesophageal reflux disease, vol. 20. Front Gastrointes tinal Research. Basel: Karger, 1992: 45-53.Johnson AG. Domperidone in the treatment of gastroesophageal reflux disease. In: Scarpignato C, ed. Advances in drug therapy of gastroesophageal reflux disease, vol. 20. Front Gastrointes tinal Research. Basel: Karger, 1992: 45-53.Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum, 1993, 36: 696-708.Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum, 1993, 36: 696-708.Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol, 1984, 19(suppl 96): 127-36.Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol, 1984, 19(suppl 96): 127-36.Van Neuten J. Effects of domperidon on gastric motility: a study on isolated stomach of the pig. Janssen Pharmaceutica, Janssen Research information service, 1977. Preclinical Research Report R33 812/30.Van Neuten J. Effects of domperidon on gastric motility: a study on isolated stomach of the pig. Janssen Pharmaceutica, Janssen Research information service, 1977. Preclinical Research Report R33 812/30.Weihrauch T, Forster C, Krieglsten J. Evaluation of the effect of domperidon on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgraduate Med J, 1979, 55(Supll. 1): 7-11.Weihrauch T, Forster C, Krieglsten J. Evaluation of the effect of domperidon on human oesophageal and gastroduodenal motility by intraluminal manometry. Postgraduate Med J, 1979, 55(Supll. 1): 7-11.Baeryens R, van de Velde E, de Schepper A et al. Effects of intravenosus and oral domperidon on the motor function of the stomach and small intestine. Postgraduate Med J, 1979, 55(Supll. 1): 19-23.Baeryens R, van de Velde E, de Schepper A et al. Effects of intravenosus and oral domperidon on the motor function of the stomach and small intestine. Postgraduate Med J, 1979, 55(Supll. 1): 19-23.Hilland U, Bohnet H, Blank M. Domperidon simulated prolactin secretion in normal male and female volunteers. Endokrinologie, 1981, 77: 363-366.Hilland U, Bohnet H, Blank M. Domperidon simulated prolactin secretion in normal male and female volunteers. Endokrinologie, 1981, 77: 363-366.Millan MJ, Peglion JL, Vian J et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (1)-S 14297: 1-activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther., 1995, 275: 885-898.Millan MJ, Peglion JL, Vian J et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (1)-S 14297: 1-activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther., 1995, 275: 885-898.Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet, 1981, 6: 61-70.Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet, 1981, 6: 61-70.Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the excretion and metabolism of domperidone in rats, dog and man. Eur J Drug Metab Pharmacokinet, 1981, 6: 49-60.Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the excretion and metabolism of domperidone in rats, dog and man. Eur J Drug Metab Pharmacokinet, 1981, 6: 49-60.Huang Y-C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJP.Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol, 1986, 26: 628-32. 18. AGA Technical Review on Nausea and Vomiting. American Gastroenterological Association (AGA) Clinical Practice and Practice Economics Committee. Gastroenterology, 2001, 120: 263-286.Huang Y-C, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants JJP.Pharmacokinetics and dose proportionality of domperidone in healthy volunteers. J Clin Pharmacol, 1986, 26: 628-32. 18. AGA Technical Review on Nausea and Vomiting. American Gastroenterological Association (AGA) Clinical Practice and Practice Economics Committee. Gastroenterology, 2001, 120: 263-286.Quinn N. Fortnightly Review: Drug treatment of Parkinson’s disease. BMJ, 1995, 310: 575-579.Quinn N. Fortnightly Review: Drug treatment of Parkinson’s disease. BMJ, 1995, 310: 575-579.Spiller RC. ABC of the upper gastrointestinal tract: Anorexia,nausea, vomiting, and pain. BMJ, 2001, 323, 1354-1357.Spiller RC. ABC of the upper gastrointestinal tract: Anorexia,nausea, vomiting, and pain. BMJ, 2001, 323, 1354-1357.Galmiche JP, Letessier E and Scarpignato C. Fort nightly review: Treatment of gastrooesophageal reflux disease in adults. BMJ, 1998, 316: 1720-1723.Galmiche JP, Letessier E and Scarpignato C. Fort nightly review: Treatment of gastrooesophageal reflux disease in adults. BMJ, 1998, 316: 1720-1723.Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology, 2004, 127: 1239-55.Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology, 2004, 127: 1239-55.De Vault KR et al. ACG Treatment Guideline: Updated Guidelines for diagnosis and treatment of gastroesophageal reflux disease. 1999, 94(6): 1434-1442.De Vault KR et al. ACG Treatment Guideline: Updated Guidelines for diagnosis and treatment of gastroesophageal reflux disease. 1999, 94(6): 1434-1442.Arora AS, Castell DO. Medical Therapy for gastroesophageal reflux disease. Mayo Clin. Proc., 2001, 76: 102-106.Arora AS, Castell DO. Medical Therapy for gastroesophageal reflux disease. Mayo Clin. Proc., 2001, 76: 102-106.Cochrane Library. Central Register of Controlled Trials and Database of Systematic Reviews. www.cochrane.org.Cochrane Library. Central Register of Controlled Trials and Database of Systematic Reviews. www.cochrane.org.PubMed. A service of National Library of Medicine and National Institutes of Health. www.pubmed.gov.PubMed. A service of National Library of Medicine and National Institutes of Health. www.pubmed.gov.Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol, 2005 Jun, 59(6): 725-9.Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol, 2005 Jun, 59(6): 725-9.Инструкция http://grls.rosminzdrav.ru.Инструкция http://grls.rosminzdrav.ru.

The authors declare that there are no conflicts of interest present.